It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cognitive dysfunction and dementia are critical symptoms of Lewy Body dementias (LBD). Specifically, alpha-synuclein (αSyn) accumulation in the hippocampus leading to synaptic dysfunction is linked to cognitive deficits in LBD. Here, we investigated the pathological impact of αSyn on hippocampal neurons. We report that either αSyn overexpression or αSyn pre-formed fibrils (PFFs) treatment triggers the formation of cofilin-actin rods, synapse disruptors, in cultured hippocampal neurons and in the hippocampus of synucleinopathy mouse models and of LBD patients. In vivo, cofilin pathology is present concomitantly with synaptic impairment and cognitive dysfunction. Rods generation prompted by αSyn involves the co-action of the cellular prion protein (PrPC) and the chemokine receptor 5 (CCR5). Importantly, we show that CCR5 inhibition, with a clinically relevant peptide antagonist, reverts dendritic spine impairment promoted by αSyn. Collectively, we detail the cellular and molecular mechanism through which αSyn disrupts hippocampal synaptic structure and we identify CCR5 as a novel therapeutic target to prevent synaptic impairment and cognitive dysfunction in LBD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Porto, Neurodegeneration Team, Nerve Regeneration Group, IBMC -Instituto de Biologia Molecular e Celular and i3S - Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
2 Colorado State University, Department of Biochemistry and Molecular Biology, Fort Collins, USA (GRID:grid.47894.36) (ISNI:0000 0004 1936 8083)
3 University of Porto, Addiction Biology Group, IBMC -Instituto de Biologia Molecular e Celular and i3S - Instituto de Investigação e Inovação em Saúde, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
4 University of California, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
5 University Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331)
6 University Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331); Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany (GRID:grid.411984.1); Framlington Place, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212); Scientific employee with an honorary contract at Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany (GRID:grid.1006.7)
7 Centro Hospitalar Universitário de Santo António, Neuropathology Unit, Porto, Portugal (GRID:grid.1006.7); University of Porto, Autoimmune and Neuroscience Research Group, UMIB – Unit for Multidisciplinary Research in Biomedicine, ICBAS – School of Medicine and Biomedical Sciences, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); ITR – Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
8 Creative Bio-Peptides, Rockville, USA (GRID:grid.5808.5)